Table 5.

Incidence of Treatment-related Adverse Events

		Cycle 1 and Cross-over Cycle 2 ABI-007 n = 15						Cycle 1 and Cross-over Cycle 2 Taxol n = 16						Cycle 3 ABI-007 and Beyond n = 13
Toxicity		Grade 1-2		Grade 3		Grade 4		Grade 1-2		Grade 3		Grade 4		Grade 1-2		Grade 3		Grade 4
Body as a whole		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
	Alopecia	5	33					6	37.5
	Anorexia/weight loss	1	7					2	12.5					1	8
	Arthralgia/Pain	2	13					2	12.5					3	23
	Fatigue							4	25					4	31
	Headache	2	13					1	6					1	8
	Hypersensitivity reaction															1	8
Blood/Bone marrow changes
	Anemia	1	7	1	7			1	6					2	15	2	15
	Thrombocytopenia															2	15
	Leukopenia	1	7	1	7	1	7	4	25	2	12.5					2	15	1	8
	Neutropenia			2	13	2	13	1	6	3	19			1	8	2	15	3	23
	Lymphopenia			3	20	1	7			2	12.5					1	8
	Febrile neutropenia			1	7											1	8
Digestive system
	Mucositis	2	13					1	6
	Nausea/vomiting	5	33					2	12.5					5	38
	Diarrhea	1	7					2	12.5	1	6			1	8
	Dyspepsia							2	12.5
	Dysgeusia	2	13					1	6					3	23
	Flatulence/Abdominal distention	1	7	1	7
Pulmonary/Cardiovascular system
	Dyspnea	1	7									1	6
Nervous/Muscular system
	Dizziness	1	7					2	12.5					2	15
	Neuropathy:sensory	2	13					2	12.5					2	15	1	8
	Muscle weakness							1	6	1	6
Metabolic/Laboratory abnormalities
	Increased PTT			1	7			2	12.5	1	6			1	8
	Hypermagnesemia															2	15
	Hypocalcemia													1	8	2	15
	Hypophosphatemia									1	6
	Hypokalemia															1	8